Researchers across academia and biopharma use NULISA to better stratify patients for disease progression and therapeutic response, strengthen the utility of brain-derived p-tau217 testing and expand into new biology including eMTBR-tau and TDP-43 Researchers across academia and biopharma use NULISA to better stratify patients for disease progression and therapeutic response, strengthen the utility of brain-derived…
Researchers across academia and biopharma use NULISA to better stratify patients for disease progression and therapeutic response, strengthen the utility of brain-derived p-tau217 testing and expand into new biology including eMTBR-tau and TDP-43
Researchers across academia and biopharma use NULISA to better stratify patients for disease progression and therapeutic response, strengthen the utility of brain-derived p-tau217 testing and expand into new biology including eMTBR-tau and TDP-43
NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Intel Corporation (“Intel” or the “Company”) (NASDAQ: INTC) securities… ...
New OVHcloud Connect locations in Amsterdam, Brussels, Frankfurt and Zurich extend private access to trusted European cloud services through ServiceFabric® ...
New class action for Better Home & Finance urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/20/2026 ...